NIOX Group (LSE:NIOX) reported first-half Revenue of £24.0m and adjusted EBITDA of £8.3m on 29 September 2026, both below the prior year, but kept full-year expectations unchanged. The AIM-quoted company also proposed a £12.5m tender offer at 80p per share, subject to Shareholder approval.

NIOX interim results: what was announced

NIOX Group published interim results for the six months ended 30 June 2026 at 07:00 on Tuesday, followed at 07:01 by details of a proposed tender offer and notice of general meeting.

Group revenue was £24.0m, compared with £25.2m in the first half of 2025. Clinical revenue rose 3% to £20.6m, while revenue from clinical trial services fell to £3.4m from £5.2m. Gross Margin improved to 71% from 70%. Adjusted EBITDA was £8.3m (H1 2025: £9.2m) and adjusted Basic Earnings Per Share was 1.98p (H1 2025: 2.24p). Cash stood at £16.8m at 30 June 2026, with no debt, compared with £11.8m a year earlier.

The company said the fall in clinical trial services revenue reflected a normalisation of trial activity after an unusually high comparative period, together with a strategic decision to prioritise available inventory for the Clinical Business ahead of the NIOX PRO® rollout.

Product and operational progress

NIOX highlighted CE Mark and UK MHRA approval for NIOX PRO®, a transition from NIOX VERO® to NIOX PRO® without backorders, a 10-year exclusive sensor Supply agreement, a price increase in Japan from 1 June 2026, and the full deployment of its US field-based sales team in March. A final Dividend of 1.55p per share (£6.5m) was paid on 22 June 2026.

Chief executive Jonathan Emms said the company expects the second half of the year to be better than the first, adding: "The Board remains confident of delivering full-year revenue and adjusted EBITDA in line with current consensus market expectations."

Tender offer: terms and timetable

The company proposes to buy back up to 15,625,000 ordinary shares at 80p each, returning up to £12.5m. According to the circular announcement, the tender price is a 22.0% premium to the mid-market closing price of 65.6p on the latest practicable date and a 26.9% premium to the three-month volume-weighted average price of 63.1p. The shares represent about 3.7% of the 420,866,313 shares in issue.

Tendered shares will be bought by the company's broker as principal, and the company will then repurchase them from the broker and cancel them. Each qualifying shareholder has a basic entitlement of about 3.7% of their holding, with the option to tender more. The tender needs a special resolution at a general meeting at 11:00 on 21 October 2026 in Oxford.

The board said a tender offer "would be the most appropriate method of returning Capital to Shareholders in a quick and efficient manner", in line with its stated intention to return 80% of free Cash Flow to shareholders over the medium term. Emms said the Balance Sheet allowed this "while retaining the financial flexibility to continue investing in the business for future growth."

Risks for this AIM stock

Revenue and profit both fell in the first half, so the full-year target depends on an improved second half. Clinical trial services revenue is tied to clinical trial activity, which can vary. The interim statement put pro forma cash after the tender at about £5.0m, which is a smaller buffer than before.

What investors may watch next

Key dates for shareholders on the UK stock market are 20 October 2026 (tender closing at 13:00 and Record Date at 18:00), the general meeting on 21 October, and settlement through CREST by 27 October. Beyond that, investors may watch second-half trading, the NIOX PRO® rollout, US sales progress and development of the MyNO® home-use device.

The bigger picture for NIOX

A softer first half sits alongside a tender offer that puts the capital return policy into action. Second-half delivery is the main test.